Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5471713 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Participants receiving GSK5471713 | EXPERIMENTAL | Participants will receive GSK5471713, according to their allocated dose level guided by the dose escalation study design. |
| Name | Type | Description |
|---|---|---|
| GSK5471713 | DRUG | GSK5471713 will be administered at different dose levels based on the dose escalation study design |
Inclusion Criteria: * Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate. * Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT). * Eastern Cooperative Oncology Group (ECOG) performance statu...
GSK5471713 is an investigational small molecule developed by GSK plc for the treatment of prostate neoplasms. It is currently in Phase 1 clinical development and is being studied in adults with metastatic castration-resistant prostate cancer (mCRPC). It has not been approved by any regulatory agency.
GSK5471713 is being evaluated for the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). It is an investigational therapy in Phase 1 testing and is not approved for any indication. The ongoing study enrolls adult male patients aged 18 years and older.
GSK5471713 is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the Phase 1 first-time-in-human study evaluating the compound in patients with metastatic castration-resistant prostate cancer.
GSK5471713 is in Phase 1 clinical development. It is an investigational small molecule and has not received FDA approval. The single ongoing trial is a first-time-in-human study that is currently recruiting participants with metastatic castration-resistant prostate cancer.
GSK5471713 is being studied in one active clinical trial, NCT07332455, titled First-Time-in-Human Study of GSK5471713 in Adults With mCRPC. The Phase 1 trial is recruiting 54 participants across the United States, Australia, Canada, France, Japan, Netherlands, South Korea, and Spain. It is an uncontrolled study.